Tasly Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Public, Subsidiary
- Established
- 1998-04-30
- Employees
- 9.2K
- Market Cap
- -
- Website
- https://www.taslypharma.com
Clinical Trials
25
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase III Clinical Study on Efficacy y and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children
- Conditions
- Cough
- Interventions
- Drug: High dose Susu Xiao'er Zhike GranulesDrug: Extremely-low dose Susu Xiao'er Zhike Granules
- First Posted Date
- 2025-01-14
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 360
- Registration Number
- NCT06773117
- Locations
- 🇨🇳
The First Teaching Hospital of Tianjin University of TCM, Tianjin, Tianjin, China
Efficacy and Safety of Changkang Granules in the Treatment of Irritable Bowel Syndrome With Predominant Diarrhea (Liver qi Affecting the Spleen Pattern)
- Conditions
- Diarrhea-predominant Irritable Boewl Syndrome
- Interventions
- Drug: Changkang Granules placebo
- First Posted Date
- 2024-12-31
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 520
- Registration Number
- NCT06753890
- Locations
- 🇨🇳
Baoding First Traditional Chinese Medicine Hospital, Baoding, China
🇨🇳No. 5, Beixiange Street, Xuanwu District, Beijing, Beijing, China
🇨🇳The Second Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, China
A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold
- Conditions
- Common Cold
- Interventions
- Drug: Antiwei Granules Placebo
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 480
- Registration Number
- NCT06697886
- Locations
- 🇨🇳
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, Beijing, China
🇨🇳changsha Hospital Affiliated to Hunan University, Changsha, China
🇨🇳Chengdu Pidu District Hospital of TCM, Chengdu, China
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
- Conditions
- Postprandial Distress Syndrome
- Interventions
- Drug: Lianxiaxiaopi GranulesDrug: a simulated agent of Lianxiaxiaopi Granules
- First Posted Date
- 2024-11-20
- Last Posted Date
- 2025-06-04
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 342
- Registration Number
- NCT06696261
- Locations
- 🇨🇳
Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing, Beijing, China
🇨🇳Gansu Provincial Hospital of Traditional Chinese Medicine, Lanzhou, Gansu, China
🇨🇳The First Affiliated Hospital of Guizhou University of Traditional Chinese Medicine, Guiyang, Guizhou, China
Efficacy and Safety of Xiangjurupining Capsule for Hyperplasia of Mammary Glands
- Conditions
- Hyperplasia of Mammary Glands
- Interventions
- Drug: Xiang Ju Ru Pi Ning capsule PlaceboDrug: Xiang Ju Ru Pi Ning capsule
- First Posted Date
- 2024-11-13
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Tasly Pharmaceutical Group Co., Ltd
- Target Recruit Count
- 430
- Registration Number
- NCT06685978
- Locations
- 🇨🇳
Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, Beijing, China
🇨🇳East Hospital of Beijing University of Chinese Medicine, Beijing, Beijing, China
🇨🇳Guang 'anmen Hospital, Beijing, Beijing, China
- Prev
- 1
- 2
- 3
- 4
- 5
- Next